JAZZ

Jazz Pharmaceuticals plc

243.47

Jul 02 • 04:00PM ET +5.96 (2.51%)

Healthcare Biotechnology Ireland Large NASD

Peers: ALNY BMRN EXEL INCY NBIX IONS RPRX VRTX LGND ASND

| Held by: IJH VTI VB VBR VXF MDY VFLO IJK SPMD IWR

Scroll to Statements

Index	-
Market Cap	15.29B
Enterprise Value	17.84B
Income	29.49M
Sales	4.44B
Book/sh	72.29
Cash/sh	45.76
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2890
IPO	Jun 01, 2007

P/E	-
Forward P/E	9.46
PEG	0.18
P/S	3.45
P/B	3.37
P/C	5.32
P/FCF	12.05
EV/EBITDA	11.42
EV/Sales	4.02
Quick Ratio	1.85
Current Ratio	2.04
Debt/Eq	1.20
LT Debt/Eq	0.96
Option/Short	Yes / Yes

EPS (ttm)	-0.02
EPS next Y	25.75
EPS next Q	6.16
EPS this Y	202.63%
EPS next Y	1.53%
EPS next 5Y	52.39%
EPS past 3/5Y	-17.69% -
Sales past 3/5Y	5.26% 12.54%
EPS Y/Y TTM	-94.01%
Sales Y/Y TTM	9.20%
EPS Q/Q	392.19%
Sales Q/Q	19.05%
Earnings	May 05 AMC
EPS/Sales Surpr.	36.60% 9.22%

Insider Own	4.56%
Insider Trans	-3.61%
Inst Own	103.83%
Inst Trans	5.95%
ROA	0.25%
ROE	0.68%
ROIC	0.33%
Gross Margin	72.85%
Oper. Margin	19.12%
Profit Margin	0.66%
SMA20	4.78%
SMA50	7.50%
SMA200	35.42%
Trades

Shs Outstand	62.70M
Shs Float	59.95M
Short Float	6.57%
Short Ratio	4.17
Short Interest	3.94M
52W High	243.32 0.06%
52W Low	105.00 131.88%
Volatility	3.16% 2.99%
ATR (14)	6.88
RSI (14)	63.22
Beta	0.33
Rel Volume	0.81
Avg Volume	945.40K
Volume	765,282

Perf Week	7.63%
Perf Month	7.67%
Perf Quarter	29.32%
Perf Half Y	42.53%
Perf YTD	43.22%
Perf Year	121.50%
Perf 3Y	96.39%
Perf 5Y	34.14%
Perf 10Y	72.62%
Recom	1.57
Target Price	260.39
Prev Close	237.51
Price	243.47
Change	2.51%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-26	Resumed	Truist	Buy	$256
May-22-26	Initiated	Bernstein	Mkt Perform	$229
May-19-26	Upgrade	UBS	Neutral → Buy	$307
Apr-10-26	Resumed	Raymond James	Outperform	$227
Feb-27-26	Initiated	Barclays	Overweight	$224
Nov-24-25	Downgrade	UBS	Buy → Neutral	$188
Jul-15-25	Initiated	Deutsche Bank	Buy	$152
Mar-07-25	Upgrade	UBS	Neutral → Buy	$145 → $179
Feb-26-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-13-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$130 → $170
Dec-12-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$140 → $175
Jun-05-24	Initiated	Goldman	Buy	$169
Jan-03-24	Initiated	Robert W. Baird	Outperform	$160
Nov-27-23	Downgrade	UBS	Buy → Neutral	$170 → $135
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight	$184 → $140
Dec-09-22	Upgrade	Goldman	Neutral → Buy	$192 → $190
Jun-14-22	Initiated	UBS	Buy	$194
Apr-06-22	Downgrade	Goldman	Buy → Neutral	$202 → $196
Nov-19-21	Resumed	Goldman	Buy	$198

Show Previous Ratings

Jul-01-26 03:45PM	Why VERAXA Biotech (VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals (NewMediaWire)
Jun-28-26 11:56PM	Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? (Stocktwits)
Jun-18-26 06:33AM	Jazz and AbCellera sign deal for T-cell engagers in solid tumours (Pharmaceutical Technology)
Jun-17-26 08:50AM	Jazz Pharmaceuticals and AbCellera Partner on Antibody Programs for Solid Tumors (InvestorsHub)
07:00AM	Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies (PR Newswire)
04:05PM	Loading…
Jun-16-26 04:05PM	Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia (PR Newswire)
Jun-12-26 08:00AM	Jazz Pharmaceuticals Provides Update on Zepzelca (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer (PR Newswire)
Jun-04-26 07:45AM	Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia (PR Newswire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
May-27-26 05:00PM	Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA (PR Newswire)
May-22-26 09:38AM	Texas Instruments, Generac upgraded: Wall Street's top analyst calls (The Fly)
May-19-26 09:34AM	StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls (The Fly)
May-12-26 04:15PM	Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences (PR Newswire)
May-06-26 08:30AM	Jazz Pharmaceuticals plc Q1 2026 Earnings Call Summary (Moby) +7.68%
May-05-26 04:31PM	Jazz: Q1 Earnings Snapshot (Associated Press)
04:05PM	Loading…
04:05PM	Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results (PR Newswire)
Apr-27-26 07:45AM	Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA (PR Newswire)
Apr-21-26 04:15PM	Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 (PR Newswire)
04:05PM	Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca (lurbinectedin) (PR Newswire)
Apr-10-26 09:37AM	Nike downgraded, IBM initiated: Wall Street's top analyst calls (The Fly)
Apr-09-26 07:45AM	Jazz Pharmaceuticals to Present Research on Epidiolex (cannabidiol) and Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting (PR Newswire)
Apr-01-26 04:15PM	Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference (PR Newswire)
Mar-24-26 01:49PM	American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education (PR Newswire)
Mar-18-26 07:44AM	Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 (PR Newswire)
Mar-09-26 11:40AM	JAZZ or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Mar-06-26 03:17PM	Taco Bell Parent, Data Center Play And Two Other Stocks Weather War Storm, Hover Near Highs (Investor's Business Daily)
Mar-05-26 08:02PM	Saniona AB (FRA:30S) Q4 2025 Earnings Call Highlights: Strategic Partnerships and Financial ... (GuruFocus.com)
Mar-03-26 03:24PM	Jazz Pharmaceuticals plc (JAZZ) Reports $1.2 Billion Q4 Revenue, Beats $1.17B Estimate (Insider Monkey)
Mar-02-26 10:37AM	Zymeworks Q4 Earnings Call Highlights (MarketBeat)
09:15AM	Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know (Zacks)
04:27AM	Loading…
Mar-01-26 04:27AM	Is Jazz Pharmaceuticals (JAZZ) One of the Best Cheap Biotech Stocks to Buy Now? (Insider Monkey)
Feb-27-26 09:54AM	Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock? (Zacks)
08:51AM	Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress (Insider Monkey)
07:59AM	Here Are Fridays Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More (24/7 Wall St.)
Feb-26-26 07:55AM	Company News for Feb 26, 2026 (Zacks)
Feb-25-26 07:55PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) +13.23%
03:51PM	Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why (StockStory)
12:49PM	Stock Market Today: Nasdaq, Dow Hold Gains Before Nvidia Earnings; Vertiv, Keysight Advance (Live Coverage) (Investor's Business Daily)
11:19AM	Stock Market Today: Dow Advance Melts Before Nvidia Earnings; Missile Firm L3Harris Eyes Entry (Live Coverage) (Investor's Business Daily)
10:56AM	JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations (Zacks)
10:24AM	Stock Market Today: Dow Up 100 Points Before Nvidia Earnings; This Drug Firm Breaks Out (Live Coverage) (Investor's Business Daily)
08:30AM	Jazz Pharmaceuticals plc Q4 2025 Earnings Call Summary (Moby)
12:08AM	Jazz Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
12:04AM	Jazz Pharmaceuticals PLC (JAZZ) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Feb-24-26 08:00PM	Jazz (JAZZ) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:30PM	Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates (Zacks)
04:30PM	Jazz: Q4 Earnings Snapshot (Associated Press Finance)
04:20PM	Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales (StockStory)
12:08PM	AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
Feb-23-26 07:03PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Feb-22-26 10:10PM	Jazz Pharmaceuticals Earnings: What To Look For From JAZZ (StockStory)
Feb-19-26 09:15AM	What Analyst Projections for Key Metrics Reveal About Jazz (JAZZ) Q4 Earnings (Zacks)
Feb-18-26 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy? (Zacks)
08:36AM	Ovintiv to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
Feb-17-26 04:15PM	Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences (PR Newswire)
10:00AM	Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-11-26 08:36AM	Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock? (Zacks)
Feb-10-26 04:15PM	Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 (PR Newswire)
Feb-09-26 07:51AM	Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-03-26 07:56AM	New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings (Zacks)
06:55AM	Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial (Insider Monkey)
Jan-30-26 12:39PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
Jan-27-26 12:22PM	Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? (Motley Fool)
Jan-26-26 10:15AM	Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? (Zacks)
Jan-16-26 06:24AM	Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading (BioPharma Dive)
Jan-15-26 12:41PM	JPM26: Jazz sells PRV for $200m, targets deals in 2026 (Pharmaceutical Technology)
Jan-13-26 07:43AM	Jazz Pharmaceuticals price target raised to $235 from $210 at Needham (TipRanks)
Jan-09-26 12:19PM	Jazz Pharmaceuticals touts Phase 3 zanidatamab OS win in HER2+ GEA, eyes FDA sBLA in H1 (MarketBeat)
Jan-08-26 07:50PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) -5.38%
04:05PM	Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer (PR Newswire)
Jan-06-26 01:32PM	Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit (PR Newswire)
Dec-28-25 10:37PM	Reflecting On Pharmaceuticals Stocks' Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) (StockStory)
Dec-17-25 11:03PM	3 Reasons JAZZ is Risky and 1 Stock to Buy Instead (StockStory)
04:15PM	Jazz Pharmaceuticals to Participate in Upcoming Investor Events (PR Newswire)
Dec-05-25 11:30AM	Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue? (Zacks)
09:00AM	Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting (PR Newswire)
07:12AM	Trials, Sales Wins Sends Jazz Pharmaceuticals Higher (FX Empire)
Dec-02-25 04:05PM	Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Nov-26-25 09:13AM	Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner (Zacks)
Nov-24-25 09:41AM	Booking, Carvana upgraded: Wall Street's top analyst calls (The Fly)
09:20AM	Here are Mondays Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More (24/7 Wall St.)
Nov-20-25 01:37AM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Nov-18-25 04:15PM	Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference (PR Newswire) +6.13%
12:16PM	JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data (Zacks)
03:38AM	Zymeworks to change course, pursue royalty-driven biotech model (BioPharma Dive)
12:43AM	Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial (Insider Monkey)
Nov-17-25 07:29PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) +20.57%
04:44PM	Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer (Investor's Business Daily)
04:13PM	Stocks to Watch Recap: Alphabet, Tesla, Netflix, Zymeworks (The Wall Street Journal)
11:41AM	Why Is Jazz Pharmaceuticals (JAZZ) Stock Soaring Today (StockStory)
09:35AM	Stocks to Watch Monday: Alphabet, Tesla, Netflix, Zymeworks (The Wall Street Journal)
09:15AM	Why Jazz (JAZZ) International Revenue Trends Deserve Your Attention (Zacks)
08:10AM	Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. (Barrons.com)
06:00AM	Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (PR Newswire)
Nov-12-25 12:36AM	The Top 5 Analyst Questions From Jazz Pharmaceuticals's Q3 Earnings Call (StockStory)
Nov-11-25 07:45AM	Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025 (PR Newswire)
Nov-06-25 10:50AM	JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View (Zacks)
12:33AM	JAZZ Q3 Deep Dive: New Drug Launches and Portfolio Expansion Drive Strong Results (StockStory)
12:01AM	Jazz Pharmaceuticals PLC (JAZZ) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Nov-05-25 07:00PM	Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Co-Founder & ChairmanMr. Bruce C. Cozadd

PresidentMs. Renee D. Gala

Executive VP & CFOMr. Philip L. Johnson

Executive VP & Chief Legal OfficerMs. Neena M. Patil J.D.

Executive VPDr. Robert Iannone M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bruce C Cozadd	Officer	Jul 01 '26	Proposed Sale	240.47	6,000	1,442,820		Jul 01 03:55 PM
Smith Mark Douglas	Director	Jun 15 '26	Sale	230.55	1,157	266,746	9,680	Jun 17 04:45 PM
MARK D SMITH	Director	Jun 15 '26	Proposed Sale	230.55	1,157	266,746		Jun 15 04:09 PM
Patil Neena M	EVP & Chief Legal Officer	Jun 10 '26	Sale	231.83	1,200	278,196	51,549	Jun 12 04:14 PM
NEENA PATIL	Officer	Jun 10 '26	Proposed Sale	231.83	1,200	278,196		Jun 10 04:04 PM
COZADD BRUCE C	Director	Jun 01 '26	Sale	235.12	6,000	1,410,720	372,682	Jun 03 05:09 PM
Bruce C Cozadd	Officer	Jun 01 '26	Proposed Sale	235.12	6,000	1,410,720		Jun 01 04:13 PM
Patil Neena M	EVP & Chief Legal Officer	May 28 '26	Sale	236.97	1,192	282,468	52,626	Jun 01 04:09 PM
Pearce Samantha	EVP, Chief Commercial Officer	May 28 '26	Option Exercise	109.45	6,907	755,971	57,179	Jun 01 04:06 PM
Pearce Samantha	EVP, Chief Commercial Officer	May 28 '26	Sale	235.41	6,907	1,625,977	50,272	Jun 01 04:06 PM
Mulligan Seamus	Director	May 28 '26	Option Exercise	138.08	3,415	471,543	1,183,028	Jun 01 04:01 PM
NEENA PATIL	Officer	May 28 '26	Proposed Sale	236.97	1,192	282,468		May 28 04:21 PM
SAMANTHA PEARCE	Officer	May 28 '26	Proposed Sale	235.41	6,907	1,625,977		May 28 04:18 PM
Winningham Rick E	Director	May 22 '26	Option Exercise	138.08	3,415	471,543	12,308	May 27 06:13 PM
Winningham Rick E	Director	May 22 '26	Sale	241.57	2,741	662,143	9,567	May 27 06:13 PM
McSharry Heather Ann	Director	May 22 '26	Sale	241.00	2,000	482,000	18,449	May 27 06:07 PM
HEATHER MCSHARRY	Director	May 22 '26	Proposed Sale	241.00	2,000	482,000		May 22 04:27 PM
RICK WINNINGHAM	Director	May 22 '26	Proposed Sale	241.57	2,741	662,143		May 22 04:13 PM
COZADD BRUCE C	Director	May 01 '26	Sale	203.33	6,000	1,219,980	378,682	May 05 04:27 PM
Bruce C Cozadd	Officer	May 01 '26	Proposed Sale	203.33	6,000	1,219,980		May 01 03:44 PM
COZADD BRUCE C	Director	Apr 01 '26	Sale	190.50	6,000	1,143,010	384,682	Apr 03 05:09 PM
Bruce C Cozadd	Officer	Apr 01 '26	Proposed Sale	190.50	6,000	1,143,010		Apr 01 04:03 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 09 '26	Sale	182.94	1,287	235,444	6,512	Mar 09 05:15 PM
PATRICIA CARR	Officer	Mar 09 '26	Proposed Sale	182.94	1,287	235,444		Mar 09 04:26 PM
Carr Patricia	Officer	Mar 05 '26	Proposed Sale	188.69	2,723	513,803		Mar 05 02:48 PM
Henderson Mary Elizabeth	Officer	Feb 26 '26	Proposed Sale	188.69	2,643	498,708		Mar 05 01:58 PM
COZADD BRUCE C	Director	Mar 03 '26	Sale	186.44	6,000	1,118,613	405,796	Mar 04 04:24 PM
Bruce C Cozadd	Officer	Mar 03 '26	Proposed Sale	186.44	6,000	1,118,613		Mar 03 02:35 PM
RIEDEL NORBERT G	Director	Feb 27 '26	Option Exercise	138.08	3,415	471,543	10,439	Mar 02 05:36 PM
RIEDEL NORBERT G	Director	Feb 27 '26	Sale	192.00	3,415	655,680	7,024	Mar 02 05:36 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 26 '26	Sale	194.11	1,253	243,222	10,352	Mar 02 05:14 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '26	Sale	190.91	1,117	213,243	9,235	Mar 02 05:14 PM
Patil Neena M	EVP & Chief Legal Officer	Feb 26 '26	Option Exercise	127.23	51,000	6,488,700	83,946	Mar 02 05:06 PM
Patil Neena M	EVP & Chief Legal Officer	Feb 26 '26	Sale	191.56	55,600	10,650,482	56,862	Mar 02 05:06 PM
Henderson Mary Elizabeth	SVP, Technical Operations	Feb 26 '26	Sale	194.49	5,343	1,039,134	28,728	Mar 02 05:04 PM
PATRICIA CARR	Officer	Feb 27 '26	Proposed Sale	190.91	1,117	213,243		Feb 27 04:22 PM
NORBERT RIEDEL	Director	Feb 27 '26	Proposed Sale	192.00	3,415	655,680		Feb 27 04:12 PM
NEENA PATIL	Officer	Feb 26 '26	Proposed Sale	191.56	55,600	10,650,480		Feb 26 04:14 PM
Carr Patricia	Officer	Feb 26 '26	Proposed Sale	196.83	2,370	466,487		Feb 26 04:08 PM
Henderson Mary Elizabeth	Officer	Feb 26 '26	Proposed Sale	196.83	10,116	1,991,132		Feb 26 03:48 PM
Henderson Mary Elizabeth	SVP, Technical Operations	Dec 09 '25	Sale	169.51	2,238	379,366	19,508	Dec 11 05:19 PM
MARY ELIZABETH HENDERSON	Officer	Dec 09 '25	Proposed Sale	169.51	2,238	379,365		Dec 09 06:52 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 05 '25	Option Exercise	140.67	4,500	633,015	11,512	Dec 09 05:25 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 05 '25	Sale	171.20	4,660	797,783	7,012	Dec 09 05:25 PM
PATRICIA CARR	Officer	Dec 05 '25	Proposed Sale	171.20	4,660	797,783		Dec 05 04:03 PM
O'Keefe Kenneth W	Director	Dec 02 '25	Proposed Sale	176.59	1,249	220,561		Dec 01 08:55 PM
COZADD BRUCE C	Director	Nov 26 '25	Option Exercise	123.36	77,500	9,560,400	470,832	Dec 01 06:14 PM
COZADD BRUCE C	Director	Nov 26 '25	Sale	177.81	77,500	13,780,337	393,332	Dec 01 06:14 PM
BRUCE COZADD	Director	Nov 26 '25	Proposed Sale	177.81	77,500	13,780,337		Nov 26 05:37 PM
McSharry Heather Ann	Director	Nov 20 '25	Option Exercise	138.08	3,415	471,543	23,864	Nov 24 05:47 PM
McSharry Heather Ann	Director	Nov 20 '25	Sale	177.78	3,415	607,127	20,449	Nov 24 05:47 PM
COZADD BRUCE C	Director	Nov 18 '25	Sale	181.09	18,000	3,259,538	390,826	Nov 20 08:03 PM
Carr Patricia	SVP, Chief Accounting Officer	Nov 18 '25	Option Exercise	136.18	5,250	714,945	12,262	Nov 20 06:13 PM
Carr Patricia	SVP, Chief Accounting Officer	Nov 18 '25	Sale	182.06	5,319	968,402	7,012	Nov 20 06:13 PM
Winningham Rick E	Director	Nov 18 '25	Sale	180.86	5,500	994,728	8,893	Nov 20 05:54 PM
HEATHER MCSHARRY	Director	Nov 20 '25	Proposed Sale	177.78	3,415	607,127		Nov 20 04:05 PM
Henderson Mary Elizabeth	Officer	Nov 19 '25	Proposed Sale	127.23	2,961	376,740		Nov 19 08:59 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Nov 17 '25	Sale	168.26	7,159	1,204,573	72,628	Nov 19 08:31 PM
Bruce C Cozadd	Officer	Nov 18 '25	Proposed Sale	181.09	18,000	3,259,537		Nov 18 07:08 PM
RICK WINNINGHAM	Director	Nov 18 '25	Proposed Sale	180.86	5,500	994,728		Nov 18 05:20 PM
PATRICIA CARR	Officer	Nov 18 '25	Proposed Sale	182.06	5,319	968,402		Nov 18 04:59 PM
ROBERT IANNONE	Officer	Nov 17 '25	Proposed Sale	168.26	7,159	1,204,573		Nov 17 04:06 PM
COZADD BRUCE C	Director	Oct 03 '25	Sale	140.00	3,500	490,000	408,826	Oct 03 09:27 PM
COZADD BRUCE C	Director	Oct 01 '25	Sale	131.78	2,000	263,560	412,326	Oct 03 09:27 PM
Bruce C Cozadd	Officer	Oct 03 '25	Proposed Sale	140.00	3,500	490,000		Oct 03 04:10 PM
COZADD BRUCE C	Director	Sep 02 '25	Sale	128.62	6,000	771,690	429,973	Sep 04 05:48 PM
Winningham Rick E	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 03:02 PM
Kennedy Patrick	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:56 PM
ENRIGHT PATRICK G	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:46 PM
RIEDEL NORBERT G	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:40 PM
Smith Mark Douglas	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:33 PM
Hamill Laura	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:26 PM
O'Keefe Kenneth W	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:20 PM
Cook Jennifer E.	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:13 PM
McSharry Heather Ann	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:06 PM
ORiordan Anne	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:00 PM
COZADD BRUCE C	Chairman & CEO	Aug 01 '25	Sale	113.21	1,000	113,210	435,973	Aug 05 04:54 PM
COZADD BRUCE C	Officer	Aug 01 '25	Proposed Sale	121.80	9,000	1,096,210		Aug 01 03:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

JAZZ

Jazz Pharmaceuticals plc

Upgrade your Finviz experience